Important Information for Intellia Therapeutics Securities Holders: Rosen Law Firm Announces Class Action Lawsuit and Lead Plaintiff Deadline
Rosen Law Firm, a leading global investor rights law firm, reminds purchasers of Intellia Therapeutics, Inc. (NASDAQ: NTLA) securities between July 30, 2024, and January 8, 2025 (the “Class Period”), of the significant deadline approaching in a securities class action lawsuit. This notice is for those who may have purchased or acquired Intellia securities during the Class Period.
Details of the Class Action Lawsuit
The lawsuit alleges that Intellia Therapeutics and certain of its top executives made materially false and misleading statements and failed to disclose material information during the Class Period. Specifically, the complaint alleges that the defendants made false and/or misleading statements and/or failed to disclose that: (1) the clinical trial data for Intellia’s lead product candidate, INT-200, was flawed; (2) the clinical trial data for INT-200 did not support the efficacy and safety of the product; (3) Intellia was experiencing manufacturing challenges; and (4) as a result, the defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Impact on Intellia Therapeutics Securities Holders
If you purchased or otherwise acquired Intellia securities during the Class Period and suffered a loss as a result, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline in this action is April 14, 2025. If you wish to serve as lead plaintiff, you must move the Court no later than this date. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Impact on the World
The outcome of this class action lawsuit could have significant implications for the biotechnology industry, particularly for companies focusing on gene editing technologies. The allegations in this lawsuit highlight the importance of transparency and accuracy in clinical trial data reporting. If the defendants are found to have made false or misleading statements, it could deter investors from putting their trust in biotech companies without a solid foundation of reliable data.
Conclusion
If you purchased Intellia Therapeutics securities during the Class Period, you may be eligible to join the class action lawsuit and potentially recover compensation. The lead plaintiff deadline is April 14, 2025. For more information, please contact Rosen Law Firm at 866-767-3653 or [email protected]. The firm represents investors worldwide, focusing its practice on securities class action and shareholder derivative litigation.
Rosen Law Firm takes pride in being a leader in the field of investor rights litigation and has recovered hundreds of millions of dollars for investors. While the outcome of any case cannot be guaranteed, the firm believes its reputation and extensive experience make it uniquely positioned to successfully handle cases of this nature. For more information about the firm, please visit
- Rosen Law Firm announces class action lawsuit against Intellia Therapeutics.
- Class Period: July 30, 2024, to January 8, 2025.
- Lead plaintiff deadline: April 14, 2025.
- Potential compensation for securities holders.
- Allegations of false and misleading statements.
- Implications for the biotechnology industry.
